RecruitingNot ApplicableNCT06208137

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

456 participants

Start Date

Feb 29, 2024

Study Type

INTERVENTIONAL

Conditions

Transplant-Related Disorder

Summary

To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Health monitoring and regular return follow-up reminders for people with transplant-related disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.